A Phase I/Ib Trial of MK-3475 (Pembrolizumab) and Afatinib in EGFR-Mutant Non-small Cell Lung Cancer With Resistance to Erlotinib
Phase of Trial: Phase I
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Afatinib (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 01 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Oct 2018.
- 10 Jun 2017 Biomarkers information updated
- 25 Jan 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.